Don't bet your entire month's sales goals on an unproven product. Build a financial plan that succeeds even if the launch underperforms. This removes pressure and allows for a more realistic assessment of the new SKU's market fit.

Don't innovate on everything. Perfectly copy 'proven' elements, make incremental 'better' improvements all users want, and only then introduce one 'new' novel idea. This isolates your bets and de-risks the innovation process.

Hexclad's product development filter is binary. New products must either be a complete reinvention of the category (like their "weapon" of a pepper mill) or, if reinvention isn't possible (like with knives), they must be so aesthetically desirable ("sexy") that they become a statement piece. Anything else is rejected.

Instead of fearing failure, Ridge institutionalizes it by allocating a $1M annual budget specifically for testing new product expansions. This removes pressure from any single launch, encourages aggressive experimentation, and has led to eight-figure successes alongside predictable flops like watches.

Amphenol functions as a continuous innovation partner, not just a component supplier. A quarter of its annual sales come from products launched within the prior four years. This highlights its ability to co-develop custom solutions for emerging technological needs and avoid commoditization.

LEGO maintains its market leadership by replacing half of its product portfolio—around 450 products—every single year. This aggressive renewal cycle forces the company to stay deeply connected to current trends and continuously innovate, ensuring they are "no better than the creativity we are coming out with right now."

Breakthrough product ideas often originate from observing successful patterns in completely different product categories and asking how that success could be adapted to your own market, as seen in the creation of Cool Ranch Doritos.

To de-risk a new idea, first anchor it in elements that are *Proven* to work in the market. Then, add a feature that is clearly *Better* for users. This isolates your *New* high-risk innovation, increasing the odds of success by not failing for the wrong reasons.

Multi-product companies can operate like internal venture funds. Hims treats each of its clinical categories as a separate "bet." This portfolio approach allows them to fund promising lines, starve underperforming ones, and protect exploratory projects, fostering innovation within a public company structure.